Drug companies’ political committees have largely donated to Republican presidential campaigns since 1990, but that trend has noticeably reversed come the 2020 election cycle, according to a new report from the Center for Responsive Politics.
Bay Area-based Genentech launched a new study assessing the company’s rheumatoid arthritis drug Actemra as a potential treatment for COVID-19 with an eye toward increasing diversity and inclusion among patients treated.
75 top Alzheimer’s and dementia experts collaborated on a 10-year strategic plan for researchers, policymakers and caregivers May 21, 2020 –– A new report released today by AARP and the Women’s Alzheimer’s Movement (WAM) synthesizes years of data and findings to help explain why women are disproportionately affected by Alzheimer’s disease. Two-thirds of the 5.8 […]
Recent reports revealed that the infection rates between adults and children were similar since the novel coronavirus hit the world in 2019, but men are more likely to exhibit severe symptoms. The report also highlights the importance of contact tracing to help mitigate infection rates.
According to a study released by Infogroup, a provider of data and data-driven intelligence solutions, four in five consumers say they are more concerned about privacy than they used to be – a tendency marketers ought to keep in mind.
Concern about clinical trial transparency, or more accurately the lack of transparency, is an ongoing problem. A new report shows that the lack of transparency also extends to post-marketing commitments that companies agreed to, following regulatory approval of a drug.
Digital Science launched a report on the state of open access monographs. The report addresses the question of how the company integrates and values monographs in the increasingly open digital scholarly network.
Despite saber-rattling, Congressional hearings, public shaming, rules regarding pricing transparency and more, the cost of spending on prescription drugs in the United States has actually increased and will likely do so for the next several years.
The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.
Medicare’s hospital insurance fund will be depleted in 2026, as previously forecast, and Social Security program costs are likely to exceed total income in 2020 for the first time since 1982, according to a government report.